OGT introduces new array CGH interpretation software

Oxford, UK – 10 December 2009. OGT, the pioneer of microarray-based technologies, has introduced its new CytoSure^® Interpret software, for faster and easier translation of oligo aCGH data into meaningful results. This new release builds on OGT’s previous software package with the addition of significant functionality such as the ‘Accelerate’ workflow, for speeding-up and streamlining the analysis and interpretation of aCGH data. Developed through consultation with users, CytoSure Interpret ensures that cytogeneticists and molecular biologists benefit from highly flexible workflows and in-depth contextual information for clearer data interpretation.

Dr. Agne Liedén from the Department of Molecular Medicine and Surgery, Karolinska Institutet commented: “I am extremely impressed with the ease-of-use and flexibility of the new CytoSure Interpret software. The main highlight for me is that I can include data from our own results, multiple annotation tracks for known CNVs from all major sources, as well as the population analysis tool.”

The CytoSure Interpret ‘Accelerate’ function enables the automation of data analysis workflows, minimising the need for user intervention and maximising the consistency and speed of data interpretation. Users are able to tailor the software to their needs, customising numerous functions including normalisation, aberration detection and report generation. Importantly, CytoSure Interpret provides comprehensive contextual input by fully integrating results with legacy data, confirmation probe information (including FISH and MLPA), as well as extensive annotation tracks covering syndromes, genes, exons, CNVs and recombination hotspots. Furthermore, these link to publicly available databases such as Decipher and the Database of Genomic Variants to provide even greater context.

James Clough, Commercial Director at OGT, stated: “The advanced functionality of CytoSure Interpret is a result of our ongoing and extremely valuable discussions with our users. We believe that CytoSure Interpret offers a step-change in the analysis and interpretation of aCGH data, enabling researchers to handle large volumes of data to move our understanding forward.”

In addition to this advanced interpretation software, the OGT CytoSure aCGH product line includes a range of high quality arrays covering single disorders through to entire syndrome spreads, as well as SciGene automation instrumentation (now distributed in Europe by OGT). As a result, OGT’s comprehensive products and services are the ideal solution for running oligo aCGH in the laboratory.

About OGT

OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell^®, CytoSure^® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.

For more information on the Company, please visit our website at ogt.com

CytoSure^®, SureSeq™ and myProbes^®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.

About Sysmex Corporation

Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.

For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.